CN115066252A - Peptide-containing composition, method for producing same, and use of peptide - Google Patents
Peptide-containing composition, method for producing same, and use of peptide Download PDFInfo
- Publication number
- CN115066252A CN115066252A CN202080090073.8A CN202080090073A CN115066252A CN 115066252 A CN115066252 A CN 115066252A CN 202080090073 A CN202080090073 A CN 202080090073A CN 115066252 A CN115066252 A CN 115066252A
- Authority
- CN
- China
- Prior art keywords
- composition
- extract
- chicken
- peptide
- collagen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 137
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 66
- 238000004519 manufacturing process Methods 0.000 title claims description 38
- 239000000284 extract Substances 0.000 claims abstract description 89
- 150000003839 salts Chemical class 0.000 claims abstract description 80
- 241001465754 Metazoa Species 0.000 claims abstract description 36
- 239000000419 plant extract Substances 0.000 claims abstract description 32
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 29
- CAVKXZMMDNOZJU-UHFFFAOYSA-N Gly-Pro-Ala-Gly-Pro Natural products C1CCC(C(O)=O)N1C(=O)CNC(=O)C(C)NC(=O)C1CCCN1C(=O)CN CAVKXZMMDNOZJU-UHFFFAOYSA-N 0.000 claims abstract description 16
- 241000287828 Gallus gallus Species 0.000 claims description 122
- 210000000845 cartilage Anatomy 0.000 claims description 70
- 102000000503 Collagen Type II Human genes 0.000 claims description 62
- 108010041390 Collagen Type II Proteins 0.000 claims description 62
- SLRNWACWRVGMKD-UHFFFAOYSA-N L-anserine Natural products CN1C=NC(CC(NC(=O)CCN)C(O)=O)=C1 SLRNWACWRVGMKD-UHFFFAOYSA-N 0.000 claims description 39
- MYYIAHXIVFADCU-QMMMGPOBSA-N anserine Chemical compound CN1C=NC=C1C[C@H](NC(=O)CC[NH3+])C([O-])=O MYYIAHXIVFADCU-QMMMGPOBSA-N 0.000 claims description 39
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims description 39
- 108010087806 Carnosine Proteins 0.000 claims description 38
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims description 37
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims description 37
- 229940044199 carnosine Drugs 0.000 claims description 37
- 108010085443 Anserine Proteins 0.000 claims description 35
- 241000210053 Potentilla elegans Species 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 32
- 206010061218 Inflammation Diseases 0.000 claims description 29
- 230000004054 inflammatory process Effects 0.000 claims description 28
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 claims description 27
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 claims description 27
- 235000013305 food Nutrition 0.000 claims description 25
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 102000004889 Interleukin-6 Human genes 0.000 claims description 20
- 108090001005 Interleukin-6 Proteins 0.000 claims description 20
- 102000000585 Interleukin-9 Human genes 0.000 claims description 20
- 108010002335 Interleukin-9 Proteins 0.000 claims description 20
- 229940100601 interleukin-6 Drugs 0.000 claims description 20
- 229940118526 interleukin-9 Drugs 0.000 claims description 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 19
- 150000001413 amino acids Chemical group 0.000 claims description 17
- 102000004127 Cytokines Human genes 0.000 claims description 11
- 108090000695 Cytokines Proteins 0.000 claims description 11
- 102000013462 Interleukin-12 Human genes 0.000 claims description 11
- 108010065805 Interleukin-12 Proteins 0.000 claims description 11
- 102000000704 Interleukin-7 Human genes 0.000 claims description 11
- 108010002586 Interleukin-7 Proteins 0.000 claims description 11
- 229940117681 interleukin-12 Drugs 0.000 claims description 11
- 229940100994 interleukin-7 Drugs 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 11
- 102000004890 Interleukin-8 Human genes 0.000 claims description 10
- 108090001007 Interleukin-8 Proteins 0.000 claims description 10
- 235000013361 beverage Nutrition 0.000 claims description 10
- 229940096397 interleukin-8 Drugs 0.000 claims description 10
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 230000028327 secretion Effects 0.000 claims description 4
- 230000004968 inflammatory condition Effects 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 102000000018 Chemokine CCL2 Human genes 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 101100450563 Mus musculus Serpind1 gene Proteins 0.000 description 81
- 210000004027 cell Anatomy 0.000 description 35
- 230000000694 effects Effects 0.000 description 31
- 102000003777 Interleukin-1 beta Human genes 0.000 description 27
- 108090000193 Interleukin-1 beta Proteins 0.000 description 27
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 21
- 238000011282 treatment Methods 0.000 description 21
- 239000003480 eluent Substances 0.000 description 16
- 239000007788 liquid Substances 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 208000002193 Pain Diseases 0.000 description 15
- 230000002401 inhibitory effect Effects 0.000 description 15
- 102000004190 Enzymes Human genes 0.000 description 14
- 108090000790 Enzymes Proteins 0.000 description 14
- 229940088598 enzyme Drugs 0.000 description 14
- 239000000843 powder Substances 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 13
- 230000002757 inflammatory effect Effects 0.000 description 13
- 239000012141 concentrate Substances 0.000 description 12
- 235000008504 concentrate Nutrition 0.000 description 12
- 239000003550 marker Substances 0.000 description 12
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 208000006820 Arthralgia Diseases 0.000 description 10
- 102000008186 Collagen Human genes 0.000 description 10
- 108010035532 Collagen Proteins 0.000 description 10
- 230000037396 body weight Effects 0.000 description 10
- 229920001436 collagen Polymers 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000000902 placebo Substances 0.000 description 9
- 229940068196 placebo Drugs 0.000 description 9
- 239000012264 purified product Substances 0.000 description 9
- 238000005194 fractionation Methods 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 238000012549 training Methods 0.000 description 8
- 210000001612 chondrocyte Anatomy 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 238000007619 statistical method Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 235000019253 formic acid Nutrition 0.000 description 6
- 230000003301 hydrolyzing effect Effects 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- 229910021642 ultra pure water Inorganic materials 0.000 description 6
- 239000012498 ultrapure water Substances 0.000 description 6
- 102000000589 Interleukin-1 Human genes 0.000 description 5
- 108010002352 Interleukin-1 Proteins 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 208000024765 knee pain Diseases 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000013589 supplement Substances 0.000 description 5
- 239000004365 Protease Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 238000005227 gel permeation chromatography Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 208000027866 inflammatory disease Diseases 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102100030500 Heparin cofactor 2 Human genes 0.000 description 3
- 101710153650 Heparin cofactor 2 Proteins 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- -1 inorganic acid salt Chemical class 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical class CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 102100023688 Eotaxin Human genes 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical class NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 235000021120 animal protein Nutrition 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- 229960001911 glucosamine hydrochloride Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 239000000413 hydrolysate Substances 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 238000002552 multiple reaction monitoring Methods 0.000 description 2
- 238000007837 multiplex assay Methods 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- OLWOKAYJAHHSNY-QRPNPIFTSA-N (2s)-2-(3-aminopropanoylamino)-3-(3-methylimidazol-4-yl)propanoic acid;nitric acid Chemical compound O[N+]([O-])=O.CN1C=NC=C1C[C@H](NC(=O)CCN)C(O)=O OLWOKAYJAHHSNY-QRPNPIFTSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- ZHQQRIUYLMXDPP-SSDOTTSWSA-N Actinidine Natural products C1=NC=C(C)C2=C1[C@H](C)CC2 ZHQQRIUYLMXDPP-SSDOTTSWSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- SLRNWACWRVGMKD-QMMMGPOBSA-N Balenine Chemical group CN1C=NC(C[C@H](N=C(O)CCN)C(O)=O)=C1 SLRNWACWRVGMKD-QMMMGPOBSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- 102100031092 C-C motif chemokine 3 Human genes 0.000 description 1
- 101710155856 C-C motif chemokine 3 Proteins 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 108090000746 Chymosin Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 108090000270 Ficain Proteins 0.000 description 1
- 208000001034 Frostbite Diseases 0.000 description 1
- 102100022887 GTP-binding nuclear protein Ran Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 1
- 101000978392 Homo sapiens Eotaxin Proteins 0.000 description 1
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 102100026236 Interleukin-8 Human genes 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 108010093008 Kinins Proteins 0.000 description 1
- 102000002397 Kinins Human genes 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000012901 Milli-Q water Substances 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010028570 Myelopathy Diseases 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010034203 Pectus Carinatum Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 241000097929 Porphyria Species 0.000 description 1
- 208000010642 Porphyrias Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 101150084062 RAN gene Proteins 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 108090000787 Subtilisin Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010043121 Tarsal tunnel syndrome Diseases 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 108090000350 actinidain Proteins 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000008445 altitude sickness Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 229940080701 chymosin Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940079919 digestives enzyme preparation Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 235000019836 ficin Nutrition 0.000 description 1
- POTUGHMKJGOKRI-UHFFFAOYSA-N ficin Chemical compound FI=CI=N POTUGHMKJGOKRI-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000019734 interleukin-12 production Effects 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 230000017073 interleukin-7 production Effects 0.000 description 1
- 230000017076 interleukin-9 production Effects 0.000 description 1
- 238000010829 isocratic elution Methods 0.000 description 1
- 230000037231 joint health Effects 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002763 monocarboxylic acids Chemical class 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- GNOLWGAJQVLBSM-UHFFFAOYSA-N n,n,5,7-tetramethyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=C(C)C=C2C(N(C)C)CCCC2=C1C GNOLWGAJQVLBSM-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003349 osteoarthritic effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229940127558 rescue medication Drugs 0.000 description 1
- 208000001076 sarcopenia Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 210000002517 zygapophyseal joint Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/275—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of animal origin, e.g. chitin
- A23L29/281—Proteins, e.g. gelatin or collagen
- A23L29/284—Gelatin; Collagen
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention aims to provide a novel composition containing an animal extract and/or a plant extract and a peptide, which has an anti-inflammatory effect. The present invention relates to a composition containing an animal extract and/or a plant extract and a peptide consisting of an amino acid sequence represented by Gly-Pro-Ala-Gly-Pro (SEQ ID NO:1) and/or a salt thereof.
Description
Technical Field
The present invention relates to compositions containing animal and/or plant extracts and peptides, and methods for producing the same. The invention also relates to the use of the peptides for the production of anti-inflammatory compositions.
Background
Collagen, known as gelatin, has been widely used in the food field. Since collagen, which is an animal protein, is a main component of dermis and connective tissue, recently, collagen has also received attention in the medical field and the cosmetic field. Generally, oral administration of high molecular weight collagen is not effectively utilized in vivo. Recently, in order to promote the intake of collagen in vivo, low molecular weight collagen peptides obtained by hydrolyzing high molecular weight collagen have been developed, and foods and/or beverages containing such collagen peptides have also been developed.
Inflammation is a phenomenon in which histamine, kinins, etc. are released by damaged cells, causing vasodilation, increase in capillary permeability, and accumulation of macrophages at an inflammation site, which results in increased blood flow at an infection site, edema, immune cell and antibody transfer, pain, fever, etc.
Recently, ingredients capable of inhibiting the expression of proteins associated with inflammation have been studied to provide effective relief of inflammation. Although anti-inflammatory agents having various mechanisms, such as non-steroidal anti-inflammatory drugs (NSAIDs) and steroidal anti-inflammatory drugs (SAIDs), have been developed, these agents may have side effects. Thus, there is still a need for ingredients that are safer and have anti-inflammatory effects.
For example, patent document 1 discloses an anti-inflammatory composition containing, as an active ingredient, a peptide derived from telomerase having an anti-inflammatory activity.
CITATION LIST
Patent document
PTL 1:JP 2015-525768 T
Disclosure of Invention
Technical problem
The present invention aims to provide novel compositions comprising animal and/or plant extracts and peptides. The present invention also aims to provide compositions having an anti-inflammatory effect.
Technical scheme
The present inventors have conducted studies to find peptides having anti-inflammatory activity. As a result, they found that a peptide consisting of the amino acid sequence shown in SEQ ID NO. 1 had anti-inflammatory activity.
The present inventors also used peptides in combination with animal extracts and/or plant extracts. As a result, they found that the anti-inflammatory activity was increased due to a synergistic effect, and thus completed the present invention.
Specifically, the present invention is defined as follows.
(1) A composition comprising an animal extract and/or a plant extract, and a peptide consisting of an amino acid sequence represented by Gly-Pro-Ala-Gly-Pro (SEQ ID NO:1) and/or a salt thereof.
(2) The composition according to the above (1), wherein the peptide and/or salt thereof is a peptide and/or salt of hydrolyzed type II collagen derived from chicken cartilage.
(3) The composition according to the above (1) or (2), wherein the composition comprises hydrolyzed type II collagen of chicken cartilage.
(4) The composition according to any one of the above (1) to (3), wherein the animal extract is a chicken extract.
(5) The composition according to any one of the above (1) to (4), wherein the composition comprises carnosine and/or anserine and/or one or more salts thereof.
(6) The composition as described in (5) above, wherein the weight ratio of the total weight of carnosine, anserine and salts thereof in terms of carnosine and anserine to the weight of the peptide and salts thereof in terms of peptide (total of carnosine and anserine/peptide) is 5000/1 to 50/1.
(7) The composition according to any one of the above (1) to (6), wherein the composition is a food, a drink or a pharmaceutical.
(8) The composition according to any one of the above (1) to (7), wherein the composition is used for reducing inflammation.
(9) The composition according to any one of the above (1) to (8), wherein the composition inhibits production of at least one cytokine selected from the group consisting of: monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1 (MIP-1), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-9 (IL-9), and stimulated regulatory normal T cell expression and secretion factors (RANTES).
(10) The composition according to any one of the above (1) to (9), wherein the composition is used for preventing or alleviating an inflammatory disorder or disease.
(11) An anti-inflammatory composition comprising, as an active ingredient, a peptide consisting of an amino acid sequence represented by Gly-Pro-Ala-Gly-Pro (SEQ ID NO:1) and/or a salt thereof.
(12) The composition of (11) above, wherein the composition inhibits production of at least one cytokine selected from the group consisting of: monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1 (MIP-1), interleukin-6 (IL-6), interleukin-7 (IL-7), interleukin-9 (IL-9), and interleukin-12 (IL-12).
(13) A method of producing a composition, the method comprising: mixing animal extract and/or plant extract with peptide composed of amino acid sequence shown by Gly-Pro-Ala-Gly-Pro (SEQ ID NO:1) and/or its salt.
(14) The method according to (13) above, wherein the mixing comprises mixing the animal extract and/or the plant extract with hydrolyzed type II collagen of chicken cartilage containing peptides and/or salts thereof.
(15) The method according to (13) or (14) above, wherein the animal extract is a chicken extract.
(16) The method of (15) above, wherein the chicken extract contains carnosine and/or anserine and/or one or more salts thereof.
(17) Use of a peptide consisting of the amino acid sequence shown by Gly-Pro-Ala-Gly-Pro (SEQ ID NO:1) and/or a salt thereof for the production of an anti-inflammatory composition.
Advantageous effects
The present invention provides novel compositions comprising animal and/or plant extracts and peptides. The composition of the present invention can be used as a food or drink composition or a pharmaceutical composition for reducing inflammation and joint pain. An animal extract and/or a plant extract and a plant extract consisting of SEQ ID NO:1 can be consumed as a food or a drink, and is also advantageous in terms of high safety.
Drawings
FIG. 1 is a flow chart schematically illustrating a method for preparing hydrolyzed type II collagen of chicken cartilage.
Fig. 2 is a graph showing the effect of hydrolyzed type II collagen (HCII) and Chicken Extract (CE) added to chicken cartilage of inflammation-inducing cells on inhibiting the production of the inflammation marker MIP-1 β.
Fig. 3 is a graph showing the effect of the combination of fraction P3, fraction P4 and fractions P3-P7 among 7 fractions obtained by fractionation of hydrolyzed type II collagen (HCII) of chicken cartilage on inhibiting the production of the inflammatory marker MIP-1 β.
Fig. 4 is a graph showing the synergistic effect of the combination of hydrolyzed type II collagen (HCII) and Chicken Extract (CE) of chicken cartilage on inhibiting the production of the inflammatory marker MIP-1 β.
FIG. 5 is a graph showing the effect of the peptide GPAGP detected in fractions P3 and P4 of hydrolyzed type II collagen (HCII) of chicken cartilage on the inhibition of the production of the inflammation marker MCP-1.
Fig. 6 is a graph showing the effect of hydrolyzed type II collagen (HCII) added to chicken cartilage of inflammation-inducing cells on the inhibition of the production of inflammatory markers.
Fig. 7 is a graph showing the effect of hydrolyzed type II collagen (HCII) and Chicken Extract (CE) of chicken cartilage, the effect of the combination of HCII and CE, and the synergistic effect of the combination of peptide GPAGP and CE in inhibiting the production of MCP-1, an inflammation marker.
FIG. 8-1(a), FIG. 8-1(b) and FIG. 8-1(c) are graphs showing the effect of the combination of HCII and CE and the combination of peptide GPAGP and CE on the inhibition of the production of the inflammatory markers IL-6 (FIG. 8-1(a)), IL-8 (FIG. 8-1(b)) and IL-9 (FIG. 8-1 (c)).
FIGS. 8-2(d), 8-2(e) and 8-2(f) are graphs showing the effect of the combination of HCII and CE and the combination of the peptides GPAGP and CE on the inhibition of the production of the inflammation markers MCP-1 (FIG. 8-2(d)), MIP-1 β (FIG. 8-2(e)) and RANTES (FIG. 8-2 (f)).
Fig. 9(a) is a graph showing the effect of a 14-day intake of hydrolyzed type II collagen (HCII) of chicken cartilage on VAS pain scores at day 7 and day 14 in each treatment group of a cohort (n ═ 151) that followed the protocol. Fig. 9(b) is a graph showing the effect of hydrolyzed type II collagen (HCII) intake of chicken cartilage on VAS pain scores at day 7 and day 14 in each treatment group of subjects who underwent less than the tenth percentile of the total resistance training period (n-8).
Detailed Description
According to an embodiment, the composition of the invention comprises an animal extract and/or a plant extract and a peptide consisting of the amino acid sequence shown by Gly-Pro-Ala-Gly-Pro (SEQ ID NO:1) and/or a salt thereof.
The composition of the present invention contains an animal extract and/or a plant extract.
Examples of the animal extract include the following extracts: mammals such as cattle, pigs, sheep and goats, birds such as poultry, quail, duck, goose, shellfish, insects, fish, mollusks, and crustaceans. Examples of plant extracts include tea extracts, fruit juices and concentrates thereof, vegetable extracts and concentrates thereof, soy beans and nut extracts.
Among these animal extracts and plant extracts, the extract is preferably an animal extract, more preferably an avian extract, still more preferably a poultry extract, and particularly preferably a chicken extract. The composition of the present invention shows higher anti-inflammatory effect when it contains chicken extract.
Chicken extract
The chicken extract (hereinafter sometimes referred to as "CE") used in the present invention may be an extract obtained by heating chicken used as a raw material in a liquid, or may be a commercially available product. The material may include bone, cartilage, legs, etc., but preferably the material does not contain head or internal organs.
Examples of commercially available products of Chicken Extract (CE) include "Brand's Essence of Chicken (BEC) (by Sun juice)&Produced by Food Asia Pte Ltd) "," Scotch TM Expression of Chicken (manufactured by Scotch Industrial Co., Ltd., Ltd.), "Quaker expression of Chicken (manufactured by Standard Foods Corporation Co., Ltd.)," "Chiken stock and cloth of SWANSON manufactured by Campbell Sound Company (NYSE: CPB)") TM "," Drip Chicken Essence produced by Eu Yan Sang International Ltd. (Singapore), "Boned Chicken Tonic produced by Eu Yan san Eu Yan Sang International Ltd. (Singapore)," and "bound Essence of Chicken produced by Hao Yi Kang Lao Xie Zhen Co., Ltd. (Taiwan province). Any such commercially available product may be used, but preferably Brand's Essence of Chicken (BEC) is used.
When the chicken extract used in the present invention is produced by hot water extraction, the chicken extract can be produced by a method commonly used in the art. For example, the chicken extract can be produced by performing normal pressure extraction and/or pressure extraction using a liquid having a temperature of 100 ℃ to 125 ℃, and treating or filtering the resulting extract with a membrane. Specifically, the extract was obtained by: a pre-treatment step (1) in which chicken is heated in a liquid; and (2) replacing the liquid with fresh liquid after the pretreatment, and heating the chicken again. The heat treatment in each of step (1) and step (2) is preferably carried out in a solvent. For example, the solvent is preferably water, ethanol or a mixture thereof. The chicken extract comprises liquid extract obtained by the above method; a dilute solution, concentrate or dry powder of the liquid extract; and purified products of these. The purified product can be obtained by, for example, subjecting the chicken extract to ultrafiltration, membrane treatment, liquid separation operation, resin fractionation treatment, or the like to increase the purity. After increasing the purity of the chicken extract, the purified product can be powdered, for example, by freeze drying or spray drying.
The chicken extract used in the present invention preferably contains carnosine and/or anserine and/or one or more salts thereof. Carnosine is beta-alanyl-histidine, which is a dipeptide of beta-alanine and histidine. Anserine is β -alanyl 1-methylhistidine in which histidine is methylated.
Examples of the carnosine salt and anserine salt include the same salts as the salts of GPAGP described later.
When the composition of the present invention contains carnosine and/or a salt thereof, for example, the amount of carnosine and/or a salt thereof in the composition is preferably 0.00001 wt% or more, more preferably 0.0001 wt% or more, and preferably 10 wt% or less, more preferably 1 wt% or less, in terms of carnosine. In an embodiment, for example, the amount of carnosine and/or a salt thereof in the composition is preferably from 0.00001 wt% to 10 wt%, more preferably from 0.0001 wt% to 1 wt%, based on carnosine.
When the composition of the present invention contains anserine and/or a salt thereof, for example, the amount of anserine and/or a salt thereof in the composition is preferably 0.00001 wt% or more, more preferably 0.0001 wt% or more, and preferably 10 wt% or less, more preferably 1 wt% or less, based on the anserine. In an embodiment, for example, the amount of anserine and/or its salts in the composition is from 0.00001 wt% to 10 wt%, more preferably from 0.0001 wt% to 1 wt%, based on anserine.
For example, carnosine, anserine and salts thereof can be quantified by HPLC.
More preferably, the composition of the invention contains both carnosine and anserine.
Peptides
The composition of the present invention contains a peptide consisting of an amino acid sequence shown by Gly-Pro-Ala-Gly-Pro (SEQ ID NO:1) and/or a salt thereof (hereinafter, "peptide consisting of an amino acid sequence shown by Gly-Pro-Ala-Gly-Pro (SEQ ID NO: 1)", which is sometimes referred to as "GPAGP").
GPAGP may be a peptide obtainable by hydrolyzing animal protein, plant protein, or the like, or may be an artificially synthesized peptide. GPAGP is preferably a peptide derived from hydrolyzed type II collagen, more preferably from chicken cartilage.
GPAGP can be purified prior to use. Alternatively, GPAGP in the form of hydrolyzed type II collagen of chicken cartilage containing GPAGP may be included in the composition. In a preferred embodiment, the composition of the invention comprises hydrolyzed type II collagen of chicken cartilage. The composition of the present invention containing hydrolyzed type II collagen of chicken cartilage exhibits higher anti-inflammatory effect.
If desired, GPAGP may be included in the compositions of the present invention as a salt with an inorganic or organic acid or as a salt with an inorganic or organic base. Such acids or bases may be selected based on the application of the salt. The following dietary acceptable salts and pharmaceutically acceptable salts are preferable in view of application to foods, beverages, medicines, and the like. Examples of the inorganic acid salt include hydrochloride, nitrate, sulfate, methanesulfonate and p-toluenesulfonate. Examples of the organic acid salt include salts with dicarboxylic acids such as oxalic acid, malonic acid, succinic acid, maleic acid, and fumaric acid, and salts with monocarboxylic acids such as acetic acid, propionic acid, and butyric acid. Examples of inorganic bases include hydroxides, carbonates and bicarbonates of sodium, lithium, calcium, magnesium and aluminium and of ammonia. Examples of the salt with an organic base include mono-alkylamine salts, di-alkylamine salts or tri-alkylamine salts (for example, salts of methylamine, dimethylamine and triethylamine), mono-hydroxyalkylamine salts, di-hydroxyalkylamine salts or tri-hydroxyalkylamine salts, guanidine salts and N-methylglucamine salts.
In the composition, the weight ratio of the total weight of carnosine, anserine, and salts thereof, calculated as carnosine and anserine, to the weight of GPAGP and salts thereof, calculated as peptide (total of carnosine and anserine/GPAGP) is preferably from 5000/1 to 1/15000. The weight ratio is more preferably 5000/1 to 50/1, and still more preferably 4000/1 to 75/1.
Hydrolyzed type II collagen of chicken cartilage
Hydrolyzed type II collagen of chicken cartilage (hereinafter, "hydrolyzed type II collagen of chicken cartilage" is sometimes referred to as "HCII") can be obtained by hydrolyzing the type II collagen with an enzyme or the like. Type II collagen can be extracted from chicken cartilage by known methods. The hydrolyzed type II collagen used in the chicken cartilage of the present invention can be prepared from cartilage by a method commonly used in the art.
For example, hydrolyzed type II collagen can be obtained by treating chicken cartilage with enzymes. In particular, hydrolyzed type II collagen can be prepared by: a pretreatment step (3) in which chicken cartilage is heated in a liquid, and a step (4) in which the chicken cartilage after the pretreatment step is treated with an enzyme. The enzyme used in step (4) is not limited as long as it is an enzyme commonly used in the art. Examples include collagenase, papain, bromelain, actinidin, ficin, cathepsin, pepsin, chymosin, trypsin, protease, aminopeptidase, subtilisin, endopeptidase and exopeptidase, and enzyme preparations obtained by mixing these enzymes. The method of preparing the hydrolyzed type II collagen is not limited to the enzyme treatment method.
The hydrolyzed type II collagen of chicken cartilage may be a solution obtained by hydrolyzing chicken cartilage, a concentrate of the solution, or a dry powder, or may be a purified product of the concentrate or the dry powder. The purified product of hydrolyzed type II collagen of chicken cartilage can be obtained by increasing the purity by, for example, subjecting a solution obtained by hydrolyzing chicken cartilage to ultrafiltration, membrane treatment, liquid separation operation, resin fractionation treatment, or the like. Hydrolyzed type II collagen of chicken cartilage is a peptide mixture, which typically contains GPAGP, and can be considered a collagen peptide derived from type II collagen.
The hydrolyzed type II collagen of chicken cartilage has a weight average molecular weight of preferably 100-. The molecular weight and weight average molecular weight can be measured by the Eurofins HPAEC-PAD method.
In embodiments, a GPAGP containing fraction, or a combination of a GPAGP containing fraction with one or more other fractions, which can be obtained by fractionation of hydrolyzed type II collagen of chicken cartilage by molecular weight by methods such as gel filtration, can be used in the composition of the present invention.
The fractions obtained by fractionation of the hydrolyzed type II collagen of chicken cartilage for the composition of the present embodiment are preferably a fraction having a molecular weight of less than 2500 and a weight average molecular weight of 900-1100 (fraction 3), and a fraction having a molecular weight of less than 1800 and a weight average molecular weight of 650-850 (fraction 4). In this embodiment, the composition preferably contains a combination of fraction 3 and fraction 4. GPAGP, a hydrolyzed type II collagen derived from chicken cartilage, is usually contained in fraction 3 and fraction 4.
The weight ratio of the hydrolyzed type II collagen of chicken cartilage (as solids) to the sum of carnosine, anserine and salts thereof (as carnosine and anserine) (hydrolyzed type II collagen of chicken cartilage/sum of carnosine and anserine) is preferably 20/1-1/5, more preferably 15/1-1/3.
The amount of each ingredient of the composition of the present invention is not limited and may be set based on, for example, the form of the composition.
In an embodiment, for example, the amount of chicken extract (on a solid basis) in the composition of the invention is preferably 0.1 wt% or more, more preferably 0.5 wt% or more, and also preferably 99 wt% or less, more preferably 90 wt% or less. In an embodiment, for example, the amount of chicken extract (on a solids basis) in the composition is preferably 0.1 wt% to 99 wt%, more preferably 0.5 wt% to 90 wt%.
In an embodiment, for example, the amount of GPAGP and/or a salt thereof in the composition of the present invention is preferably 0.0001 wt% or more, more preferably 0.001 wt% or more, and also preferably 90 wt% or less, more preferably 80 wt% or less. In embodiments, for example, the amount of GPAGP in the composition is preferably from 0.0001 wt% to 90 wt%, more preferably from 0.001 wt% to 80 wt%.
For example, in an embodiment, the amount of hydrolyzed type II collagen (on a solid basis) of chicken cartilage in the composition of the present invention is preferably 0.1 wt% or more, more preferably 0.5 wt% or more, and also preferably 99 wt% or less, more preferably 90 wt% or less. In an embodiment, for example, the amount of hydrolyzed type II collagen (on a solids basis) of chicken cartilage in the composition is preferably 0.1 wt% to 99 wt%, more preferably 0.5 wt% to 90 wt%.
Herein, the amount of hydrolyzed type II collagen of chicken cartilage includes the amount of GPAGP.
The composition of the present invention is preferably used as food, drink or medicine. Examples of the food or drink include functional claims foods (foods with function foods), health-promoting foods, foods for special diet, dietary supplements, health supplements, and general supplements. The form of the food or beverage is not limited. For example, it may be a solid food or a liquid food. Preferably a beverage.
The form of the drug is not limited. Non-limiting examples include oral preparations such as capsules, tablets, powders, granules and dry syrups; external preparations such as ointments, adhesive skin patches, eye drops, suppositories; and an injection. The medicament is preferably an oral preparation (oral medicine).
The compositions of the present invention may contain pharmaceutically or dietetically acceptable additives such as various carriers, excipients, diluents, acidulants, antioxidants, stabilizers, preservatives, flavoring or masking agents, emulsifiers, colors, seasonings, pH adjusting agents and nutritional enhancers.
The compositions of the invention are suitable for therapeutic use (medical use) and non-therapeutic use (non-medical use). "non-treatment" is a concept that does not include medical activities, i.e., a concept that does not include a method of surgery, treatment, or diagnosis in humans.
Anti-inflammatory composition
The compositions of the present invention are useful for reducing inflammation. The composition of the present invention may be an anti-inflammatory composition containing an animal extract and/or a plant extract and GPAGP and/or a salt thereof as active ingredients.
To achieve the anti-inflammatory effect (anti-inflammatory effect) contemplated by the present invention, hydrolyzed type II collagen of chicken cartilage containing GPAGP and/or a salt thereof and an animal extract and/or a plant extract (particularly, a chicken extract) are added to the composition in the same manner as described above for the composition. Hydrolyzed type II collagen of chicken cartilage containing GPAGP and/or a salt thereof and an animal extract and/or a plant extract may be used as they are, or a concentrate, a dry powder or a purified product thereof may be added as described above, as long as the effect of the present invention is not impaired. The same additives as described above may be used.
The composition of the present invention is preferably orally ingested (orally administered). The dosage (also referred to as "intake") of the composition of the present invention is not limited as long as the inflammation-reducing effect is achieved. The dosage of the composition of the present invention can be appropriately determined according to the administration form, the administration method, the body weight of the subject, and the like.
In an embodiment, when the composition of the present invention is fed or orally administered to a human (adult), the intake amount (in terms of solid) of the chicken extract is preferably 0.1mg or more, more preferably 1mg or more, and further preferably 15000mg or less, more preferably 13000mg or less per 60kg body weight per day. In embodiments, the chicken extract is preferably ingested by a human (adult) in an amount of 0.1-15000mg, more preferably 1-13000mg per 60kg body weight per day. The intake of chicken extract includes the amount of carnosine and anserine.
In an embodiment, when the composition of the present invention is orally fed or administered to a human (adult), the total dose of carnosine, anserine, and salts thereof is preferably 0.001mg or more, more preferably 0.01mg or more, and further preferably 500mg or less, more preferably 400mg or less per 60kg body weight per day, in terms of carnosine and anserine. In an embodiment, the total of carnosine, anserine and salts thereof fed to a human (adult) is preferably 0.001-500mg, more preferably 0.01-400mg per 60kg body weight per day in terms of carnosine and anserine.
In an embodiment, when the composition of the present invention is fed or orally administered to a human (adult), the intake amount of GPAGP and/or a salt thereof in terms of GPAGP is preferably 0.001mg or more, more preferably 0.01mg or more, and further preferably 200mg or less, more preferably 100mg or less per 60kg body weight per day. In an embodiment, the amount of GPAGP and/or a salt thereof ingested by a human (adult) is preferably 0.001 to 200mg, more preferably 0.01 to 100mg per 60kg body weight per day, in terms of GPAGP.
In an embodiment, when the composition of the invention is fed or orally administered to a human (adult), the amount of the intake (on a solid basis) of hydrolyzed type II collagen of chicken cartilage is preferably 0.01mg or more, more preferably 0.1mg or more, and also preferably 4000mg or less, more preferably 3000mg or less per 60kg body weight per day. In an embodiment, the amount of hydrolyzed type II collagen ingested by a human (adult) into chicken cartilage is preferably 0.01 to 4000mg, more preferably 0.1 to 3000mg per 60kg body weight per day.
Herein, the intake of hydrolyzed type II collagen of chicken cartilage includes the intake of GPAGP and/or salts thereof.
In the present invention, the above amount of chicken extract and the above amount of hydrolyzed type II collagen of chicken cartilage containing GPAGP and/or a salt thereof are preferably fed or administered at least once a day, for example, once or more times a day (e.g., twice or three times a day). In an embodiment, the aforementioned amount of chicken extract and the aforementioned amount of hydrolyzed type II collagen of chicken cartilage containing GPAGP and/or a salt thereof are preferably fed or orally administered to a human. In an embodiment, the composition of the invention may be used to feed or administer the above amount of chicken extract and the above amount of hydrolyzed type II collagen of chicken cartilage containing GPAGP and/or its salt to a human (per 60kg body weight per day).
The compositions of the present invention inhibit the production of cytokines such as monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1 (MIP-1), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-9 (IL-9), and stimulated regulation of normal T cell expression and secretion factors (RANTES). The compositions of the present invention are particularly effective in inhibiting the production of MCP-1, MIP-1 β, IL-6, IL-8, IL-9 and RANTES.
By inhibiting cytokine production, inflammation in vivo can be reduced.
The compositions of the present invention are useful for preventing or alleviating an inflammatory condition or disease. An inflammatory condition or disease is, for example, a condition or disease caused by inflammation or a condition or disease accompanied by inflammation. Examples of such conditions or diseases include collagen diseases such as arthritis and rheumatoid arthritis, inflammatory bowel disease, osteoarthritis, tendonitis, sciatica, herniated intervertebral disc, stenosis, myelopathy, back pain, facet joint pain, carpal tunnel syndrome, tarsal tunnel syndrome, post-lumbar surgery pain syndrome, AIDS, arteriosclerosis, asthma, diabetes, hepatitis, stroke, dementia, muscle atrophy, viral infection, skin aging including photoaging, cancer, aging, allergic diseases, Parkinson's disease, cerebral infarction, cataracts, epilepsy, spinal cord injury, retinopathy of prematurity, nephropathy, peptic ulcer, pancreatitis, ulcerative colitis, myocardial infarction, adult respiratory distress syndrome, emphysema, vasculitis, edema, diabetic complications, UV injury, altitude sickness, porphyria, burns, frostbite, contact dermatitis, Shock, multiple organ failure, DIC, fatigue, sarcopenia (muscle weakness), mitochondrial dysfunction, Alzheimer's disease, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, and systemic lupus erythematosus (lupus). The composition of the present invention is preferably used for preventing or alleviating these diseases. In particular, the food or beverage composition is preferably used for preventing or alleviating diseases such as osteoarthritis, rheumatoid arthritis and psoriatic arthritis.
As used herein, prevention of a condition or disease includes prevention of onset of disease, delay of onset of disease, reduction in incidence of disease, reduction in risk of onset of disease, and the like. Alleviation of a disorder or disease includes recovery of the subject from the disorder or disease, alleviation of symptoms of the disorder or disease, amelioration of symptoms of the disorder or disease, delay or prevention of progression of the disorder or disease, and the like.
The subject to which the composition of the present invention is fed or administered (which may also be referred to as "subject") is not limited. The subject is preferably a human or non-human mammal, more preferably a human.
In embodiments, the subject may be one who needs or wants to inhibit inflammation. Such a subject may be, for example, one in need or desire to prevent or reduce inflammation, or one in need or desire to prevent or reduce an inflammatory disorder or disease. In embodiments, the subject of the invention may be a middle aged or elderly human. The compositions of the present invention may also be used by healthy people, for example, for the purpose of preventing a condition that can be prevented or alleviated by attenuating inflammation.
The compositions of the present invention may be labeled with functional claims that demonstrate effects through attenuation of inflammation. Such tags are also referred to as tags with functional claims, and the content of the tags is not limited. Examples of such functional claims on the label include "relieving joint pain", "attenuating joint pain", "managing knee condition", "maintaining knee health", "improving joint mobility", and other functional claims equivalent to the above.
In an embodiment of the present invention, the composition of the present invention is preferably a food or beverage, and more preferably a beverage, which is marked with the above-mentioned functional claims. The label may describe the use of the composition of the invention to achieve the above-described functionality. The label may be added to the composition itself or to a container or package for the composition.
The present invention also relates to a method for producing a composition, which comprises the step of mixing an animal extract and/or a plant extract with a peptide consisting of an amino acid sequence shown by Gly-Pro-Ala-Gly-Pro (SEQ ID NO:1) (GPAGP) and/or a salt thereof.
In the above step, GPAGP and/or a salt thereof may be separately mixed with the animal extract and/or the plant extract. However, the composition is preferably produced by mixing hydrolyzed type II collagen of chicken cartilage containing GPAGP and/or a salt thereof with an animal extract and/or a plant extract (preferably a chicken extract). In this case, for example, a hydrolysate obtained by hydrolyzing type II collagen of chicken cartilage with an enzyme or the like can be directly used for mixing with a chicken extract. As described above, a concentrate, a dry powder or a purified product thereof may be added as long as the effect of the present invention is not impaired.
In the production method of the present invention, the order of adding the raw materials is not limited. For example, GPAGP and/or a salt thereof, or hydrolyzed type II collagen of chicken cartilage containing GPAGP and/or a salt thereof, may be first placed in a container and then chicken extract added. Alternatively, the chicken extract may be placed in a container first, and then GPAGP and/or a salt thereof, or hydrolyzed type II collagen of chicken cartilage containing GPAGP and/or a salt thereof, may be added.
Commercially available chicken extracts or chicken extracts produced by hot water extraction can be used directly in admixture with GPAGP and/or salts thereof, or hydrolyzed type II collagen of chicken cartilage containing GPAGP and/or salts thereof. However, when the chicken extract is in the form of a concentrate, a dry powder, or a purified product of the concentrate or dry powder, the chicken extract may be diluted, dissolved, etc. in a liquid (e.g., water, ethanol, or a mixture of water and ethanol) and then mixed with GPAGP, hydrolyzed type II collagen of chicken cartilage, or the like. When the hydrolyzed type II collagen of chicken cartilage containing GPAGP and/or a salt thereof is in the form of a concentrate, a dry powder, or a purified product of the concentrate or dry powder, such product may be similarly diluted, dissolved, etc. in a liquid or the like before mixing. Alternatively, such a product may be added without prior dilution, dissolution, or the like, and then mixed with a liquid to be diluted, dissolved, or the like in the liquid.
In the production method of the present invention, the chicken extract preferably contains carnosine and/or anserine and/or one or more salts thereof.
In the production method of the present invention, the preferred modes of the chicken extract are as described above. Preferred embodiments of hydrolyzed type II collagen of chicken cartilage are also described above.
The composition produced by the production method of the present invention may contain the above-mentioned additives in addition to the chicken extract, GPAGP and/or its salt, and hydrolyzed type II collagen of chicken cartilage.
The present invention also relates to an anti-inflammatory composition comprising, as an active ingredient, a peptide consisting of an amino acid sequence represented by Gly-Pro-Ala-Gly-Pro (SEQ ID NO:1) and/or a salt thereof.
Examples of the anti-inflammatory composition include compositions similar to those described above containing an animal extract and/or a plant extract and GPAGP and/or a salt thereof, however, the animal extract and/or the plant extract are not essential components in the anti-inflammatory composition. The anti-inflammatory composition may comprise the same animal extract, the same plant extract, the same hydrolyzed type II collagen of chicken cartilage containing GPAGP and/or its salt, and the same additives as described above.
The anti-inflammatory composition of the present invention inhibits the production of cytokines such as: monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1 (MIP-1), interleukin-6 (IL-6), interleukin-7 (IL-7), interleukin-9 (IL-9), and interleukin-12 (IL-12). The compositions of the present invention are particularly effective in inhibiting the production of MCP-1, MIP-1 β, IL-6, IL-7, IL-9 and IL-12.
The invention also relates to the use of peptides consisting of the amino acid sequence shown by Gly-Pro-Ala-Gly-Pro (SEQ ID NO:1) (GPAGP) and/or salts thereof for the production of anti-inflammatory compositions.
Examples of the anti-inflammatory composition include compositions similar to those described above containing an animal extract and/or a plant extract and GPAGP and/or a salt thereof, however, the animal extract and/or the plant extract are not essential components in the anti-inflammatory composition. The anti-inflammatory composition may comprise the same animal extract, the same plant extract, the same hydrolyzed type II collagen of chicken cartilage containing GPAGP and/or its salt, and the same additives as described above.
Examples
The present invention is described more specifically below with reference to examples. The invention is not limited to the embodiments described.
The raw materials, reagents and the like used in the following examples and comparative examples are as follows.
Preparation of hydrolyzed type II collagen from chicken cartilage
FIG. 1 shows a flow chart schematically describing the process for the preparation of HCII. First, frozen chicken cartilage was thawed in water at 40 ℃ and washed in water at 40 ℃ (1 hour). Next, the washing water was poured off, and the clear water was poured into a 1200L pot so that it was 3 times as much as the chicken cartilage. The water was heated to the optimum working temperature for the enzyme treatment and the washed chicken cartilage was immersed therein for the enzyme treatment for several hours. After the enzyme treatment, the pan containing the chicken cartilage was heated to 90 ℃ or higher and incubated at 90 ℃ or higher for 30 minutes, thereby inactivating the enzyme used in the previous enzyme treatment. The resulting mixture (liquid and enzyme treated chicken cartilage) was filtered. The resulting liquid was concentrated. Finally, the resulting concentrate was spray-dried at 200 ℃, thereby preparing HCII powder.
Determination of the molecular weight of HCII powder
The molecular weight distribution of the resulting HCII was determined by the Eurofins HPAEC-PAD method. Table 1 below shows the molecular weight distribution of the resulting HCII. The resulting HCII had a weight average molecular weight of 4582, calculated using methods common in the art.
TABLE 1
Fractionation of HCII fractions and analysis of peptides
(materials and methods for HCII fractionation and biological Activity identification)
(Material)
Formic acid was purchased from Tokyo Chemical Industry co. Ultrapure water was obtained from Merck Milli-Q water purification system. The synthetic peptide GPAGP was obtained from GenScript.
(preparative Gel Permeation Chromatography (GPC))
Fractionation of HCII was performed using a preparative VERITY 271HPLC system (Gilson). HC-II was dissolved in ultrapure water to prepare a solution of 10mg/mL (w/v). After centrifugation at 14000rpm for 5 minutes, a 1000. mu.L aliquot was injected onto a preparative GPC column (BioSep 5. mu.m SEC-s 2000) attached to a guard column (SecurityGuard PREP card C1215X 21.2mm ID (Phenomenex)) LC column 300 × 21.2mm (phenomenex)), and was eluted with eluent a (ultrapure water: formic acid ═ 100:0.1(v/v)) at a rate of 5mL/min for 30 minutes with isocratic elution. Chromatograms were observed at 214 nm.
Fractions were collected every 0.5 min between 8 min to 28 min using a GX series fraction collector (Gilson), and the 40 individual fractions obtained were subsequently combined into 7 fractions, P1-P7 (P1: 8.5-12.0 min, P2: 12.0-13.5 min, P3: 13.5-14.5 min, P4: 14.5-16.0 min, P5: 16.0-17.5 min, P6: 17.5-19.0 min, P7: 19.0-27.5 min). The combined fractions were evaporated to dryness in a lyophilizer (ScanVac) and the dried samples were stored at-20 ℃ until further use.
Table 2 shows the molecular weight of each fraction obtained above. In table 2, "Mw" and "Mp" represent the weight average molecular weight and the peak molecular weight, respectively. As shown in table 2, fraction 3(P3) and fraction 4(P4) consisted of molecules with average molecular weights of 1035(P3) and 784 (P4).
The molecular weights of the fractions of HCII were measured by HPLC gel filtration under the following conditions.
The instrument comprises: agilent 1100 series
And (3) detection: UV 214nm
Flow rate: 1mL/min
Mobile phase: isocratic 0.1mM sodium phosphate buffer pH 6.8
Operating time: 20 minutes
TABLE 2
Fraction(s) of | Mw | Mp |
P1 | 1359 | 1626 |
P2 | 1092 | 1494 |
P3 | 1035 | 956 |
P4 | 784 | 783 |
P5 | 422 | 213 |
P6 | 211 | 225 |
(computer search for peptides directed to GPAGP)
Fractions P1-P7 were subjected to LC-MS analysis on an Agilent HPLC 1290 series coupled TripleTOF 5600(AB Sciex) with a Duo Spray Turbo V ion source and gas generator (Peak Scientific Ltd.). The main components were separated with UHPLC Guard Zorbax Eclipse Plus C182.1 × 5mm, 1.8 μm (agilent) and eluted with eluent a (ultrapure water: formic acid 100:0.1(v/v)) and eluent B (acetonitrile: formic acid 100:0.1(v/v)) in a linear gradient as follows: 0-0.5 min: 100% eluent A; 0.5-7.5 minutes: 100% -65% of eluent A; 7.5-10.0 min: 65% -0% of eluent A; 11.0-13.0 min: 0% eluent A; 13.0-13.1 min: 0-100% eluent A; 13.1-15.0 min: 100% eluent A. The experiments were performed in position mode using an Independent Data Acquisition (IDA) method, with the Collision Energy (CE) and Declustering Potential (DP) of the MS optimized to 10.0V and 80V, respectively. The analysis was done by PeakView (AB Sciex). The mass spectral data was then analyzed and retrieved using Protein Pilot (AB Sciex) accompanied by a Unit KB fasta file, using as key. The data was further processed by candidate blacklisting and validation was done with peptides purchased from Genscript.
(detection and quantification of peptide markers by LC-MS analysis)
Detection and quantification of GPAGP peptide was performed on LC-MS. LC-MS analysis was performed on an Agilent HPLC 1290 series coupled tripleTOF 5600(AB Sciex) with a Duo Spray Turbo V ion source and gas generator (Peak Scientific Ltd.). The mass spectrometer uses electrospray ionization and Multiple Reaction Monitoring (MRM) at unit mass resolution in positive ion mode, using the following parameters: collision energy diffusion (CES): 10; delayed Ion Release (IRD): 67; ion Release Width (IRW): 25; ion source gas: 40; air curtain gas (CUR): 30, of a nitrogen-containing gas; temperature: 500.0 of the total weight of the mixture; ion spray voltage (isff): 5500. The MS compound-related parameter settings, such as declustering voltage (DP) and Collision Energy (CE), were optimized for different peptides. Analyst1.5.2(AB Sciex) was used for device control, data acquisition and data processing.
GPAGP was reconstituted in ultrapure water and injected onto a Zorbax Eclipse Plus C182.1 × 5mm, 1.8 μm (Agilent) column with UHPLC Guard Zorbax Eclipse Plus C18 RRHD 1.8 μm 2.1 × 50mm (Agilent) and eluted with eluent a (ultrapure water: formic acid 100:0.1(v/v)) and eluent B (acetonitrile: formic acid 100:0.1(v/v)) using the following linear gradient: 0-0.5 min: 100% eluent A; 0.5-10 minutes: 100% -65% of eluent A; 10-11 minutes: 65% -10% of eluent A; 11-12.5 minutes: 10% of eluent A; 12.5-14.1 min: 10% -100% of eluent A. The sample volume was 10. mu.L, the flow rate was 300. mu.3.1 Th, and the retention time was 3.1min as quantitative and qualitative substances. Calibration curves were constructed by injecting standard GPAGP at 31.5ng/mL, 62.5ng/mL, 125ng/mL, 250ng/mL, 500ng/mL into the mass spectrometer. HC-II was redissolved to 125. mu.g/mL as a working solution. Quantification of GPAGP in HC-II and its GPC fractions was done by MultiQuant (AB Sciex).
GPAGP is contained in P3 and P4 fractions of HCII, and the content of GPAGP is 914.5. + -. 121.4. mu.g/g based on 1g of HCII.
Quantification of carnosine and anserine
Quantitation of carnosine and anserine in chicken extracts was performed by HPLC under the following conditions.
A standard stock solution of carnosine was prepared by adding and dissolving carnosine powder in deionized water to a carnosine concentration of 2.50 mg/ml. The anserine standard stock solution was prepared by adding and dissolving L-anserine nitrate powder in deionized water to a L-anserine concentration of 3.96 mg/ml.
The weight of L-anserine was calculated by the following formula.
L-anserine (g) ═ 0.792 XL-anserine nitrate (g)
Analytical conditions of HPLC
The device comprises the following steps: high performance liquid chromatography system with UV detector (Agilent 1100 from Agilent Corp.)
Column: zorbax 300-SCX 4.6mm ID X250 mm (Agilent)
Mobile phase: 50mM potassium dihydrogen phosphate
Flow rate: 1.0mL/min
A flow channel: channel A (50mM potassium dihydrogen phosphate), channel B (acetonitrile), channel D (deionized water)
Wavelength of ultraviolet detector: 210nm
Sample introduction volume: 10 μ L
Method for evaluating anti-inflammatory activity
In examples and comparative examples, the effect of inhibiting the production of inflammatory markers was evaluated by the following method.
(raw materials and reagents)
Chicken Extract (CE): brand's Essence of Chicken (Sun fashion Beverage & Food Asia Pte Ltd, carnosine content in 1 ml: 0.94mg/ml, anserine content in 1 ml: 1.9mg/ml)
Chondrocyte Culture Medium (CM), Fetal Bovine Serum (FBS), Chondrocyte Growth Supplement (CGS), and penicillin/streptomycin (P/S): ScienCell Research Laboratories
IL-1β:R&D Systems
Poly-L-lysine (PLL) -coated 96-well plates (Corning)
Cell culture and pretreatment
Human chondrocytes were isolated from human articular cartilage (HC-a, science cell Research Laboratories) and maintained in CM supplemented with 5% FBS, 1% CGS and 1% P/S. Cells were seeded at a cell density of 4000 cells/well in PLL-coated 96-well plates and at 37 ℃ in the presence of 5% CO 2 Incubated overnight in the humidified chamber of (1). Chondrocytes were washed once with PBS and pre-treated with different concentrations of HCII, CE, a combination of HCII and CE, and GPAGP alone for 24 hours and further treated by addition of 25ng/mL IL-1 β for 24 hours. Cells were centrifuged at 1100g for 5 minutes and the supernatant was used for cytokine analysis.
Multiplex cytokine assay
Pro-Human Cytokine Multiplex Assays (Bio-Rad, Munich, Germany) were used to analyze cytokines in the culture medium. The following 27 re-analyses were performed: IL-1 beta, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8(CXCL8), IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, eotaxin (CCL11), macrophage colony stimulating factor (M-CSF), Interferon (IFN) -gamma, monocyte chemotactic protein 1 (MCP-1; CCL2), macrophage inflammatory protein-1 alpha (MIP-1 alpha; CCL3), MIP-1 beta (CCL4), stimulated regulation of normal T cell expression and secretion factor (TES RANs) (CCL5), TNF-alpha and Vascular Endothelial Growth Factor (VEGF). Multiplex assays were performed according to the manufacturer's instructions and run on the Luminex xPONENT for madix platform. Bio-Plex Manager version 6.0 was used for data processing. Cytokine and chemokine concentrations were calculated by reference to standard curves. The sensitivity of the multiplex kit was <5 pg/mL.
Statistical analysis
Statistical analysis was performed using GraphPad Prism version 5.0 (San Diego, california, usa). All results are expressed as mean ± standard deviation. Statistical analysis was performed by analysis of variance (ANOVA), followed by a post hoc Tukey multiple comparison test. Data were considered significant when P-value P < 0.05.
Comparative example 1, comparative example 2 and example 1
To evaluate the effect of HCII and Chicken Extract (CE) on the inflammatory marker MIP-1 β produced by human chondrocytes, the following four different conditions were compared: cells before treatment (untreated control), cells treated with IL-1 β (comparative example 1), cells treated with IL-1 β + HCII (example 1) and cells treated with IL-1 β + CE (comparative example 2). HCII-treated cells and CE-treated cells were pretreated with HCII or CE. The HCII concentration in the pretreatment was 0.5mg/ml or 2.5mg/ml and the CE concentration was 1.25mg/ml or 6.25 mg/ml.
As shown in fig. 2, 25ng/mL of IL-1 β induced inflammation in human chondrocytes, resulting in a significant increase in the level of MIP-1 β compared to untreated cells (control). Pretreatment of cells with HCII and CE reduced MIP-1 β levels induced by IL-1 β. HCII and CE also have a dose-dependent effect on the inhibition of MIP-1 β production. In fig. 2, the data are expressed as mean ± SD (n ═ 3). Unless otherwise stated, a significant difference of p <0.05, indicates p <0.01, and indicates p <0.001, compared to IL-1 β (IL-1 β treated cells).
Example 2 Effect of the combination of fractions P3, P4 and P3-P7 on inhibiting the production of the inflammatory marker MIP-1 β
Of the seven fractions isolated from HCII, P3-P7 were used. Cells were pretreated with IL-1 β and a combination of HCII, P3, P4, or P3-P7 (each at a concentration of 5mg/mL for the combination of HCII, P3, P4, and P3-P7) as in example 1 to compare the effects.
The results are shown in FIG. 3. Data are presented as mean ± SD (n ═ 3). Unless otherwise stated, a significant difference of p <0.05, p <0.01, compared to IL-1 β (IL-1 β treated cells) indicates p < 0.001.
Example 3 synergistic Effect of combination of HCII and CE
To evaluate the synergistic effect of the combination of HCII and CE in inhibiting the production of the inflammatory marker MIP-1 β, pre-treatment was performed with HCII alone, CE alone or a combination of HCII and CE. In the pretreatment, the concentration of HCII was 0.5mg/ml and the concentration of CE was 1.25 mg/ml.
As shown in FIG. 4, the combination of 0.5mg/mL HCII and 1.25mg/mL CE provided a synergistic effect in reducing inflammation compared to treatment with HCII or CE alone. Data are presented as mean ± SD (n ═ 3). Unless otherwise stated, a significant difference of p <0.05, in comparison to IL-1 β (IL-1 β treated cells), represents p <0.01, and represents p < 0.001.
Example 4 and comparative example 3 effects of GPAGP in inhibiting production of MCP-1, an inflammation marker
To evaluate the effect of HCII and GPAGP on inhibiting the production of the inflammatory marker MCP-1, the following four different conditions were compared: cells before treatment (untreated control), cells treated with IL-1 β (comparative example 3), cells treated with IL-1 β + HCII (example 4) and cells treated with IL-1 β + GPAGP (example 4). Cells were pretreated with HCII or GPAGP (example 4). In the pretreatment, the concentration of HCII was 5mg/mL, and the concentration of GPAGP was 500 mg/mL.
The results are shown in FIG. 5. Data are presented as mean ± SD (n ═ 3). Unless otherwise stated, a significant difference of p <0.05, p <0.01, compared to IL-1 β (IL-1 β treated cells) indicates p < 0.001.
Example 5 and comparative example 4
To evaluate the effect of HCII on the inflammatory markers IL-6, IL-7, IL-9 and IL-12, the following three different conditions were compared: cells before treatment (untreated control), cells treated with IL-1. beta. (comparative example 4) and cells treated with IL-1. beta. + HCII (example 5). IL-1. beta. + HCII treated cells were pretreated with HCII. In the pretreatment, the concentration of HCII was 0.5mg/ml or 2.5 mg/ml.
As shown in FIG. 6, IL-1. beta. at 25ng/mL induced inflammation in human chondrocytes, resulting in a significant increase in the level of IL-6, IL-7, IL-9 or IL-12, as compared to untreated cells (control). Pretreatment of cells with HCII reduced the levels of IL-6, IL-7, IL-9 and IL-12 induced by IL-1 β. HCII inhibits IL-6, IL-7, IL-9 and IL-12 production also has a dose-dependent effect. In fig. 6, the data are represented as mean ± SD (n-3). Unless otherwise stated, a significant difference of p <0.05, in comparison to IL-1 β (IL-1 β treated cells), represents p <0.01, and represents p < 0.001. Example 6 Effect of the combination of HCII and CE and the combination of GPAGP and CE on the inhibition of the production of MCP-1, an inflammation marker
To evaluate the effect of the combination of HCII and CE and the combination of GPAGP and CE on the inhibition of the production of MCP-1, which is an inflammatory marker, a pretreatment was performed with IL-1. beta. and either the combination of HCII and CE or the combination of GPAGP and CE as in example 1, in which the concentration of HCII was 2.5mg/ml or 5mg/ml, the concentration of GPAGP was 2.5mg/ml, and the concentration of CE was 6.25 mg/ml.
Fig. 7 shows the results. Data are presented as mean ± SD (n ═ 3). Unless otherwise stated, a significant difference of p <0.05, in comparison to IL-1 β (IL-1 β treated cells), represents p <0.01, and represents p < 0.001.
Example 7 Effect of the combination of HCII and CE and the combination of GPAGP and CE on inhibiting the production of inflammatory markers
To evaluate the effect of the combination of HCII and CE and the combination of GPAGP and CE on inhibiting the production of the inflammatory markers IL-6, IL-8, IL-9, MCP-1, MIP-1 β and RANTES, a pre-treatment with IL-1 β and the combination of HCII and CE or the combination of GPAGP and CE was performed. In the pretreatment, the concentration of HCII was 2.5mg/ml, the concentration of GPAGP was 25mg/ml, 125mg/ml or 250mg/ml, and the concentration of CE was 6.25 mg/ml.
The results are shown in FIG. 8-1(a), FIG. 8-1(b), FIG. 8-1(c), FIG. 8-2(d), FIG. 8-2(e) and FIG. 8-2 (f). Data are presented as mean ± SD (n ═ 3). Unless otherwise stated, a significant difference of p <0.05, p <0.01, compared to IL-1 β (IL-1 β treated cells) indicates p < 0.001.
Example 8 randomized, double-blind, four-arm trial study to evaluate the effects of HCII and CE on knee pain
This experimental study was conducted as a double-blind, randomized, placebo-controlled study in a single center.
(Subjects grouped and randomized)
A total of 160 subjects 45-75 years of age were selected using inclusion and exclusion criteria summarized in table 3. Subjects were randomly assigned to four groups, namely "placebo", "glucosamine", "HCII" and "HCII and CE". Each group included 40 subjects.
TABLE 3
(test products)
The "placebo" group took a mixture of 6.8g maltodextrin and 7mg xanthan gum once a day after meals in the morning.
The glucosamine group was administered once a day in the morning after meals at 1.5g glucosamine hydrochloride. Glucosamine hydrochloride served as the activity comparator.
The "HCII" group was administered BRAND' S Collagen Hydrolysate (Sun fashion juice & Food Asia Pte Ltd), a hydrolyzed chicken breast cartilage extract consisting of hydrolyzed type II Collagen (HCII) and a naturally occurring matrix of low molecular weight chondroitin sulfate and Hyaluronic Acid (HA). The product comprises HCII containing the peptide GPAGP. Each bottle with a capacity of 68mL contained 2g of HCII, providing a naturally occurring composition of HCII (66.5%), depolymerized chondroitin sulfate (18%) and HA (11%). The uncharacterized thoracic cartilage component accounted for the remaining 4.5%.
The "HCII and CE" group took 68mL of the following mixture: 70g (5-6 g dry weight) of BRAND' S Essence of chicken (BEC) and 2g of HCII.
All test products were made as liquid products in glass bottles, which were isocaloric, identical in appearance, and identical in flavor and texture. Participants had to take the study product once a day in the morning after meals.
Subjects were allowed to continue to take concomitant medications or supplements that were not believed to affect the results of the study. Analgesics or painkillers are allowed as prescribed rescue medication. The proportion of days of analgesic coverage (PDC) was calculated based on the record of the fraction of concomitant medication of the analgesic and was defined as the percentage of days of analgesic coverage to the total days of the interval between visits. Any treatment or dietary supplement that could support joint, bone and muscle health was banned throughout the study including: hormone therapy (growth hormone, progesterone, estrogen or testosterone), calcium and vitamin D, supplements rich in amino acids, peptides, proteins, omega-3, omega-6, glucosamine or chondroitin.
(procedure)
The study included a screening visit (28 days prior to baseline visit), a subsequent baseline visit (baseline visit considered day 0. screening and baseline visits may be on the same day), and 3 follow-up visits (weeks 8, 16, and 24). Subjects were screened from day-28 to day 0 to determine the eligibility of the study. Test product intake started the day after baseline visit for 168 consecutive days (24 weeks). For 168 consecutive days (24 weeks), subjects took a bottle of test product each morning (after meals). Intake compliance was recorded on a diary card.
Visual Analog Scale (VAS) of knee pain was scored at day 0, day 7 and day 14 post-ingestion.
During the study, subjects were advised to perform resistance training (optionally) twice a week at home, 30 minutes each, following the training program. The training is recorded on a diary card. The diet of the previous week of the visit was recorded using a food questionnaire.
(treatment compliance)
Compliance with study product intake was checked by collecting unused product and daily food records kept by subjects. Compliance was defined as the percentage of the indicated dose actually consumed in the days between visits. Consumption of 70% is considered compliant.
(sports plan)
All subjects were encouraged to perform 30 minutes of resistance training at home twice weekly according to the training manual provided at baseline visit. Compliance with the training program was recorded on a log card and calculated using the following formula:
Compliance rates of > 50% are considered compliant.
(visual analog Scale for Knee pain (VAS))
The Visual Analog Scale (VAS) is rated from 0 to 100mm, where 0 means no pain and 100 means the most severe pain. On days 0, 7 and 14 after ingestion, the interviewee was asked to indicate the level of pain felt by drawing a straight line on the scale indicating the position along the solid line.
(tolerance and safety)
Spontaneously reported adverse events were recorded throughout the study. Vital signs were monitored at each visit. To assess the safety of the study products, all participants were assessed for serum and urine at each visit during the study.
(statistical analysis)
Statistical analysis of the compliance program was performed according to a prior statistical analysis plan. Randomized subjects with intake compliance ≧ 70% were included in the protocol-compliant analysis. Safety parameter analysis was performed on subjects who had taken at least 28 bottles of study product. The binary variables were reported using percentages, while the continuous variables were reported as mean and SD. The chi-square test is used for categorical variable comparisons, while the krustal carl-voris test is used to compare between-group differences for continuous variables.
Repeated measures analysis of variance (ANOVA) was performed using a mixed effects model for testing the mean difference in variation between study groups, with the interaction of the interview intake as a fixed effector for consecutive primary and secondary endpoints. All results were considered statistically significant if the corresponding p-value was below 0.05. If the visit intake interaction term is significant, a post-hoc pairwise comparison between treatment groups is performed and an adjusted p-value is reported. Variables expected to affect the endpoint were included as factors in the model. Gender and gender interview interaction terms were included as factors in the joint health analysis.
In addition, a subgroup analysis was performed on subjects who underwent resistance training for less than the tenth percentile of the total training session. Independent statisticians performed analyses using SAS version 9.4 (Cary, USA).
Results
(Baseline characteristics and treatment compliance)
A total of 160 subjects were enrolled and 151 subjects completed the study and were included in the statistical analysis (PP). Nine subjects were withdrawn during the study; there was no significant difference in the number of withdrawals between groups. None of the withdrawers were associated with any side effects caused by the intake of study product or placebo. No adverse events were noted. No clinically significant changes were observed for serum biochemical markers and urinalysis.
Overall, there were no statistical differences in compliance rates between all four groups (table 4). To assess the homogeneity of the data, all parameters between the four arms were compared. There were no statistically significant differences between the study groups at baseline (table 4).
TABLE 4
(VAS Change in Knee pain score)
After 14 days of intake, the pairwise comparison between 2g HCII and placebo was statistically significant, with the 2g HCII group having less pain as measured by the VAS pain score than the placebo (p ═ 0.021). Pain scores for HCII users at day 7 were-11.1% from HCII group baseline and-25% at day 14, compared to pain scores at day 0 (figure 9(a), table 5). In fact, the placebo group showed a tendency to experience increased pain during day 14 with a 33.3% increase in pain score at day 7 and a 13.3% increase at day 14 starting at day 0.
Furthermore, a subgroup analysis of subjects trained on the tenth percentile less than the total resistance training period showed that the pain score of the placebo group experienced a significant increase of 200% from baseline at day 14 compared to the HCII group (p ═ 0.021) increase of 8.7% from day 0 (fig. 9(b), table 6). In tables 5 and 6, "P value ($)" means the P value between groups; "(a)" and "(k)" indicate methods for determining a p value ((a) ═ one-way analysis of variance, (k) ═ kruskarl-wallis test); "+" indicates statistical significance; "95% c.i." means 95% confidence interval.
In fig. 9(a) and 9(b), two values in parentheses of each data are "mean-standard deviation" and "mean + standard deviation".
TABLE 5
TABLE 6
(conclusion)
Overall, HCII is well tolerated and provides rapid and significant symptomatic relief for patients suffering from osteoarthritic pain. Compared to placebo, ingestion of 2g HCII significantly reduced knee pain within only 14 days.
In vitro studies have shown that the mechanism of action may be through modification of the underlying disease process, in particular inhibition of inflammation leading to local pain sensation. In summary, HCII and combinations of HCII and CE can be considered as safe and effective supplements to current medical and dietary options for treating OA symptoms.
INDUSTRIAL APPLICABILITY
The present invention provides novel compositions comprising peptides and animal and/or plant extracts. The composition of the present invention can be used as a food or beverage composition or a pharmaceutical composition for reducing inflammation and joint pain. The animal extract and/or the plant extract and the peptide consisting of the amino acid sequence shown by SEQ ID NO. 1 can be consumed as food or drink, and are also advantageous in terms of safety.
Sequence listing
<110> Sandeli control stock company
<120> peptide-containing composition, method for producing the same, and use of the peptide
<130> SP2020-0086
<150> SG10201913612R
<151> 2019-12-27
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 5
<212> PRT
<213> Chicken ()
<400> 1
Gly Pro Ala Gly Pro
1 5
Claims (17)
1. A composition, comprising:
animal extract and/or plant extract; and
a peptide consisting of an amino acid sequence represented by Gly-Pro-Ala-Gly-Pro (SEQ ID NO:1) and/or a salt thereof.
2. The composition of claim 1, wherein the peptides and/or salts thereof are peptides and/or salts of hydrolyzed type II collagen derived from chicken cartilage.
3. The composition of claim 1 or 2, wherein the composition comprises hydrolyzed type II collagen of chicken cartilage.
4. The composition of any one of claims 1-3, wherein the animal extract is a chicken extract.
5. A composition according to any one of claims 1 to 4, wherein the composition comprises carnosine and/or anserine and/or one or more salts thereof.
6. The composition according to claim 5, wherein the weight ratio of the total weight of carnosine, anserine and salts thereof, calculated as carnosine and anserine, to the weight of the peptide and salts thereof, calculated as peptide (sum of carnosine and anserine/peptide) is from 5000/1 to 50/1.
7. The composition of any one of claims 1-6, wherein the composition is a food, beverage, or pharmaceutical.
8. The composition of any one of claims 1-7, wherein the composition is for reducing inflammation.
9. The composition of any one of claims 1-8, wherein the composition inhibits production of at least one cytokine selected from the group consisting of: monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1 (MIP-1), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-9 (IL-9), and stimulated regulatory normal T cell expression and secretion factors (RANTES).
10. The composition of any one of claims 1-9, wherein the composition is used to prevent or alleviate an inflammatory condition or disease.
11. An anti-inflammatory composition comprising, as an active ingredient, a peptide having an amino acid sequence represented by Gly-Pro-Ala-Gly-Pro (SEQ ID NO:1) and/or a salt thereof.
12. The composition of claim 11, wherein the composition inhibits production of at least one cytokine selected from the group consisting of: monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1 (MIP-1), interleukin-6 (IL-6), interleukin-7 (IL-7), interleukin-9 (IL-9), and interleukin-12 (IL-12).
13. A method of producing a composition, the method comprising: mixing animal extract and/or plant extract with peptide composed of amino acid sequence shown by Gly-Pro-Ala-Gly-Pro (SEQ ID NO:1) and/or its salt.
14. The method of claim 13, wherein the mixing comprises mixing the animal extract and/or the plant extract with hydrolyzed type II collagen of chicken cartilage containing the peptide and/or salt thereof.
15. The method of claim 13 or 14, wherein the animal extract is a chicken extract.
16. The method of claim 15, wherein the chicken extract comprises carnosine and/or anserine and/or one or more salts thereof.
17. Use of a peptide consisting of the amino acid sequence shown by Gly-Pro-Ala-Gly-Pro (SEQ ID NO:1) and/or a salt thereof for the production of an anti-inflammatory composition.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG10201913612R | 2019-12-27 | ||
SG10201913612R | 2019-12-27 | ||
PCT/JP2020/025206 WO2021131104A1 (en) | 2019-12-27 | 2020-06-26 | Composition containing peptide, production method thereof, and use of peptide |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115066252A true CN115066252A (en) | 2022-09-16 |
Family
ID=76574108
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202080090073.8A Pending CN115066252A (en) | 2019-12-27 | 2020-06-26 | Peptide-containing composition, method for producing same, and use of peptide |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP4087656A4 (en) |
JP (1) | JP2023508935A (en) |
CN (1) | CN115066252A (en) |
AU (1) | AU2020415517A1 (en) |
TW (1) | TW202128209A (en) |
WO (1) | WO2021131104A1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003048850A (en) * | 2001-06-01 | 2003-02-21 | Nippon Meat Packers Inc | Therapeutic agent of arthropathy, and functional food |
CN101007020A (en) * | 2006-01-23 | 2007-08-01 | 周立军 | Composition of a cartilage protein and its application in medical treatment and health protection |
US20140044655A1 (en) * | 2011-02-18 | 2014-02-13 | Isp Investments Inc. | Novel activator peptides for synthesizing extracellular matrix proteins, and cosmetic compositions including same |
US20140309401A1 (en) * | 2011-11-04 | 2014-10-16 | Nippi, Incorporated | Dpp-4 inhibitor |
EP3053458A1 (en) * | 2015-01-28 | 2016-08-10 | Paninkret Chemisch-Pharmazeutisches Werk GmbH | Spray-Dried Composition Comprising an Acerola Fruit Extract and Hydrolyzed Collagen |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2900155B1 (en) * | 2006-04-21 | 2008-06-27 | Diana Naturals Sa | AVIAN CARTILAGE HYDROLISATE, PROCESS FOR OBTAINING AND USES |
KR20180091578A (en) * | 2017-02-07 | 2018-08-16 | 주식회사한국파마 | Peptide for activating ampk, and uses thereof |
-
2020
- 2020-06-26 WO PCT/JP2020/025206 patent/WO2021131104A1/en unknown
- 2020-06-26 EP EP20906055.7A patent/EP4087656A4/en active Pending
- 2020-06-26 CN CN202080090073.8A patent/CN115066252A/en active Pending
- 2020-06-26 JP JP2022538449A patent/JP2023508935A/en active Pending
- 2020-06-26 AU AU2020415517A patent/AU2020415517A1/en active Pending
- 2020-06-29 TW TW109121864A patent/TW202128209A/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003048850A (en) * | 2001-06-01 | 2003-02-21 | Nippon Meat Packers Inc | Therapeutic agent of arthropathy, and functional food |
CN101007020A (en) * | 2006-01-23 | 2007-08-01 | 周立军 | Composition of a cartilage protein and its application in medical treatment and health protection |
US20140044655A1 (en) * | 2011-02-18 | 2014-02-13 | Isp Investments Inc. | Novel activator peptides for synthesizing extracellular matrix proteins, and cosmetic compositions including same |
US20140309401A1 (en) * | 2011-11-04 | 2014-10-16 | Nippi, Incorporated | Dpp-4 inhibitor |
CN106866814A (en) * | 2011-11-04 | 2017-06-20 | 株式会社日皮 | The inhibitor of DPP 4 |
EP3053458A1 (en) * | 2015-01-28 | 2016-08-10 | Paninkret Chemisch-Pharmazeutisches Werk GmbH | Spray-Dried Composition Comprising an Acerola Fruit Extract and Hydrolyzed Collagen |
Non-Patent Citations (2)
Title |
---|
CHUN‑CHIEH CHEN等: "Randomized, double‑blind, four‑arm pilot study on the effects of chicken essence and type II collagen hydrolysate on joint, bone, and muscle functions", NUTRITION JOURNAL, 15 December 2020 (2020-12-15), pages 1 - 9 * |
朱俊颖;赵黎明;蒋丽华;邱勇隽;夏泉鸣;: "影响鸡胸肉中肌肽/鹅肌肽提取率因素的研究", 食品工业科技, no. 17, 1 September 2016 (2016-09-01), pages 210 - 214 * |
Also Published As
Publication number | Publication date |
---|---|
AU2020415517A1 (en) | 2022-07-07 |
TW202128209A (en) | 2021-08-01 |
EP4087656A4 (en) | 2023-10-18 |
WO2021131104A1 (en) | 2021-07-01 |
EP4087656A1 (en) | 2022-11-16 |
JP2023508935A (en) | 2023-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI739738B (en) | Water-soluble mussel extract | |
CN112955539A (en) | Probiotic strains against aging, muscle and bone, intestinal tract, hyperlipidemia, skin and brain | |
WO2017010538A1 (en) | Composition that contains plant- or animal-derived peptide and inhibits serum carnosinase | |
Abachi et al. | Immunomodulatory effects of fish peptides on cardiometabolic syndrome associated risk factors: A review | |
US20160331798A1 (en) | Natural product inhibitors of 3dg | |
US20080175888A1 (en) | Combination Therapy Comprising Actinidia and Steroids and Uses Thereof | |
JP6671671B1 (en) | Preventive and / or therapeutic drug for allergic rhinitis | |
CN115066252A (en) | Peptide-containing composition, method for producing same, and use of peptide | |
KR102650558B1 (en) | Probiotics composition for preventing, improving, or treating inflammatory disease containing Lactobacillus rhamnosus PL60 as an active ingredient | |
WO2021131106A1 (en) | Composition containing cyclic dipeptide, purine nucleoside and/or amino acid, and chicken extract, production method thereof, and use of cyclic dipeptide, purine nucleoside and/or amino acid, and chicken extract | |
CN115151140A (en) | Food or drink composition containing peptide and/or salt thereof, method for producing same, use of hydrolyzed type II collagen, composition for inhibiting bone resorption, and use of chicken extract | |
JP2024500803A (en) | Use of cyclic dipeptide in the production of an agent for suppressing cognitive decline or improving cognitive dysfunction | |
KR101830395B1 (en) | Composition comprising squalene for enhancement of muscle function and prevention of muscle damage | |
JP2020200288A (en) | Agent for preventing or improving osteoarthritis | |
KR20200035785A (en) | Composition for Enhancing Immunity comprising Agastachis Herba Extract as effective component | |
KR102227723B1 (en) | Composition for preventing or treating of skin diseases comprising 2-amino-2-norbornane carboxylic acid | |
TW201125573A (en) | Glucagon-like peptide-1 secretion promoter | |
KR102154284B1 (en) | Composition for Enhancing Immunity comprising Kalopanax Extract as effective component | |
KR20100109664A (en) | Composition for preventing or treating of obesity, dyslipidemia, fatty liver or insulin resistance syndrome comprising camphor as active ingredients | |
TW202402190A (en) | Composition for promoting growth comprising peptide from whey protein | |
CN113292410A (en) | Compound, composition and application of compound and composition in preparation of food, health-care product or medicine with anti-allergic effect | |
JP2023025533A (en) | Precursor fat cell differentiation inhibitor, beverage/food product, pharmaceutical and cosmetic product containing the precursor fat cell differentiation inhibitor, and method of preventing or remedying obesity or metabolic syndrome | |
Bathla et al. | Effect of Nutrients on Different Changes Associated With Aging | |
KR20150078906A (en) | Composition for preventing, improving or treating inflammatory disease comprising Pueraria Radix extract as an active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40079602 Country of ref document: HK |